While the exact reasons remain unclear, the increase is thought to be driven by several factors, including a higher prevalence of modifiable risk factors, such as excess body weight, physical inactivity, and exposure to environmental pollutants
In the STEP-1 clinical trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide
Manufacturer savings cards may be available, but for comprehensive weight management solutions, working with Klinic's prescription services for medications like Zepbound provides an insurance-friendly alternative
Current Opinion in Cell Biology
Your First Month "*" indicates required fields By submitting this form, I consent to be contacted by Sant via phone, text, email, or mail
Participants self-administered daily subcutaneous injections of tesamorelin (Theratechnologies Inc), a stabilized analog of human GHRH (1 mg/d), or a placebo 30 minutes before bedtime for 20 weeks